The occurrence of grade 4 adverse events and survival outcomes in patients with nonsquamous non-small cell lung cancer receiving bevacizumab with chemotherapy in the phase III PointBreak and AVAiL studies.
Year: 2013
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Liza Cosca Villaruz, Mark A. Socinski, Jyoti D. Patel, Larry Leon, Sebastien Hazard, Martin Reck
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2602013400